The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hepatocellular Carcinoma
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Approximately 30 patients will be enrolled and receive the following treatments: TACE (day 1, up to twice. TACE interval will be 4?6 weeks) ? Ablation (4 weeks after the last TACE, up to twice. Ablation interval will be 4?6 weeks) ? Durvalumab (at least 1 week after the last ablation, 1500 mg Q4W, u...
Approximately 30 patients will be enrolled and receive the following treatments: TACE (day 1, up to twice. TACE interval will be 4?6 weeks) ? Ablation (4 weeks after the last TACE, up to twice. Ablation interval will be 4?6 weeks) ? Durvalumab (at least 1 week after the last ablation, 1500 mg Q4W, until mRECIST criteria defined radiological progression or other discontinuation criteria were met, but no more than 1 year).
Tracking Information
- NCT #
- NCT04517227
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon